This editorial refers to 'Exercise unmasks distinct pathophysiologic features in heart failure with preserved ejection fraction and pulmonary vascular disease' † , by T.M. Gorter et al., on page 2825.
To date, no effective treatment is available for heart failure with preserved ejection fraction (HFpEF). This lack of treatment is caused by the limited understanding of the underlying pathophysiology, which in turn is at least partly due to the fact that HFpEF is not a uniform disease. In order to make therapeutic progress, we have to face the problem of patient heterogeneity, and use it to our advantage by improving patient phenotype characterization and identifying specific patient groups who could benefit from specific treatment. In this issue of the European Heart Journal, Gorter et al. 6 focus on a specific HFpEF phenotype, namely HFpEF patients with pulmonary hypertension (PH). The presence of PH in HFpEF is associated with poor clinical outcome. 1 PH is thought to occur because of the backward propagation of high left-sided filling pressures to the post-capillary pulmonary vessels, resulting in isolated post-capillary PH (IpcPH). However, in a subset of HFpEF patients with PH (PH-HFpEF), there is combined post-and pre-capillary PH (CpcPH). Although PH is common in HFpEF and prevalent in up to 83% of cases, 2 the majority of these PH-HFpEF cases have IpcPH. Still, in some patients, the diastolic pressure gradient is >7 mmHg and/or the pulmonary vascular resistance >3 Wood units. This haemodynamic pattern is consistent with a precapillary component superimposed to post-capillary pulmonary congestion and evidence of actual pulmonary vascular remodelling. 1 The prevalence of CpcPH in a prospective HFpEF cohort was determined to be 7.5%. 3 The important question is whether or not CpcPH is simply a more advanced form of HFpEF compared with IpcPH, but not a different entity. Many studies may be interpreted this way as, in general, patients with CpcPH often have higher filling pressures and longer duration of HFpEF. However, there is increasing evidence that CpcPH is much more than a worse form of IpcPH. A study by Caravita et al. investigated the ventilatory profile of CpcPH as compared with IpcPH during exercise. 4 They found a pattern resembling the combination of advanced heart failure as found in IpcPH and pulmonary arterial hypertension (PAH), suggesting that both pathophysiologies contribute to exercise intolerance. Similarly, ventilatory response and death-space ventilation were higher, and oxygen saturation lower, at submaximal exercise in CpcPH as compared to IpcPH patients. 5 The study by Gorter et al. in this issue of the European Heart Journal provides the haemodynamic background for these findings. 6 Thus, exercise was significantly limited by the deterioration of right ventricular performance, which was not present in IpcPH patients. There was a disproportionate increase in right atrial pressures during exercise, while greater elevations in pulmonary vascular resistance (PVR) were correlated with a greater reduction in left ventricular (LV) transmural pressure, reflecting pre-load of the LV. This combination led to a striking reduction in stroke volume during exercise and impaired cardiac output. Importantly, a similar cascade was not found in patients with IpcPH, although some of the haemodynamic changes were somewhere in between those of HFpEF patients without PH and patients with CpcPH. Thus, it may be speculated that right heart failure, which is often seen in HFpEF, is a consequence of the above-mentioned cascade, requiring specific therapy to reduce symptoms and to improve outcome. Still, this needs to be prospectively tested.
Little is known about why only a subset of patients develop CpcPH. Patients with CpcPH are thought to develop pulmonary vascular disease similarly to patients with PAH. An interesting pre-clinical study from van Duin et al. demonstrated a progression from IpcPH to CpcPH with time, which was accompanied by activation of the endothelin (ET) pathway. 7 This is in line with observations of elevated transpulmonary levels of ET-1 in CpcPH patients, with a strong correlation between ET-1 and PVR, suggesting that ET-1 could be not only a marker, but also a potential contributor of CpcPH. 8 that CpcPH may share molecular similarities. 9 It advocates that CpcPH is a different entity compared to IpcPH and represents a subset of PH-HFpEF patients that have a genetic predisposition to the development of pulmonary vascular remodelling in response to elevated filling pressures. It may be speculated that such genetic susceptibility is present in any disease associated with pulmonary vascular remodelling independent of the additional trigger and not restricted to HFpEF only. To investigate if and when IpcPH progresses to CpcPH, longitudinal follow-up studies are necessary. In addition, methods to assess PVR non-invasively for classification of PH are essential for the feasibility of longitudinal studies. Specific changes in parameters of exercise testing may help to non-invasively identify patients with CpcPH. 4, 5 In addition, numerous studies have investigated echocardiographic estimates of increased pulmonary vascular resistance to distinguish between pre-and post-capillary PH (e.g. Dixon et al.
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). Additionally, simultaneous right heart catheterization and echocardiography of HFpEF patients identified the ratio of tricuspid annular plane systolic excursion (TAPSE) to systolic pulmonary arterial pressure (sPAP) as an accurate non-invasive parameter to distinguish IpcPH from CpcPH. 10 However, it needs to be mentioned that echocardiographic parameters are subject to significant variability and that correlations between echocardiographic and invasive measurements are moderate to good, but not perfect. In addition, distinction between IpcPH and CpcPH during exercise using echocardiography has not been sufficiently investigated. Therefore, invasive measurements remain the gold standard in patients with suspicion of CpcPH, as done by Gorter et al. 6 The similarities in pulmonary vascular remodelling between PAH and CpcPH have led to the hypothesis that selective pulmonary vasodilator therapies may improve symptoms and outcomes in CpcPHHFpEF. In addition, the nitric oxide (NO) soluble guanylate cyclase (sGC) cyclic guanosine monophosphate (cGMP) pathway has been a major focus of investigation in HFpEF. HFpEF was shown to be associated with coronary microvascular endothelial activation, which leads to reduced NO-dependent signalling from endothelial cells to cardiomyocytes, predisposing them to hypertrophy and diastolic stiffness. Therefore, several studies with pulmonary vasodilators have been performed in HFpEF, irrespective of the presence of PH, to evaluate the effect on endothelium-cardiomyocyte signalling. For instance, a multicentre randomized control trial tested sildenafil and enrolled HFpEF patients with and without PH. 11 Administration of sildenafil for 24 weeks did not result in an improvement in exercise capacity or clinical status. A smaller single-centre trial by Guazzi et al., including only HFpEF patients with PH based on echocardiography (right-ventricular systolic pressure >40 mmHg), demonstrated an effect of sildenafil on pulmonary pressures, RV function, and exercise capacity at 1 year follow-up. 12 However, the study by Hoendermis et al. did not confirm these data, showing no improvement in exercise capacity after 12 weeks of sildenafil treatment. Although this study included PH-HFpEF patients confirmed by invasive haemodynamic measurements, it included mainly IpcPH patient and only a minority had CpcPH. 13 Riociguat, an sGC stimulator, in PH-HFpEF failed to show beneficial effects on pulmonary pressures in PH-HFpEF. 14 Taken together, the studies investigating the NO-sGC-cGMP pathway in HFpEF in general were rather disappointing and, most likely, addressed the fact that altering the microvasculature by increasing cGMP in HFpEF is not successful. In contrast, a positive effect of this therapeutic principle on CpcPH patients is possible and worth investigating. This highlights the urgent need to better differentiate the various forms of HFpEF and to better understand the underlying pathophysiology, underscoring the high value of studies such as the one by Gorter et al.
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Besides the NO-cGMP pathway, the ET pathway plays a central role in pulmonary vascular remodelling. Therefore, ET receptor antagonists (ERAs) were postulated as a therapy for CpCPH. This treatment, routinely used for patients with PAH, was tested in two trials specifically focusing on CpcPH. A pilot study evaluated the 16 Although ERAs are known for their beneficial effects on the pulmonary circulation, they may cause venous congestion. Since CpcPH is not only a pre-capillary problem like PAH but has an important additional post-capillary component, these patients are prone to venous congestion. This might explain why ERAs do not seem to be beneficial in CpcPH patients, in contrast to PAH patients. Importantly, these somewhat contradictory findings do not exclude a positive effect of targeting the pulmonary vasculature in CpcPH patients, but highlight the need for appropriate studies based on thorough phenotyping and targeting both pre-and post-capillary PH (Take home figure) .
In conclusion, the study by Gorter et al. 6 confirms the notion that
IpcPH and CpcPH are different entities; consequently, specifically addressing them might result in benefit for these patients. Therefore, the possibility of intervening on the NO-cGMP pathway should not be discarded for the treatment of HFpEF in all patients. A specific subgroup, i.e. CpcPH-HFpEF patients, could benefit since this has not yet been properly investigated. What we may learn from the trials with ERAs is that CpcPH, as a combined pre-and post-capillary problem, should be addressed by treating both issues. Treatment of venous congestion by diuretics, a cornerstone of HF therapy, seems to be equally essential in both IpcPH and CpcPH patients (Take home figure) .
